The Sean. M. Healey & AMG Center for ALS at Massachusetts General Hospital is accepting nominations for the 2022 Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative Healing in acknowledgement of the important scientific work being done in ALS.
Healey Center News & Events
Baseline Speech Assessment and Vital Capacity Measured Remotely and in Clinic in the HEALEY ALS Platform Trial
A team of researchers from the Healey ALS Platform Trial Biomarkers and Outcomes Measures taskforce have released a poster at the European Network to Cure ALS 2022 International Meeting that includes data around remote measurement of baseline speech assessment and vital capacity (VC), a measure of respiratory function.
Director of Sean M. Healey & AMG Center for ALS Named Co-chair of NINDS ALS Optimizing Clinical Research Strategic Planning Effort
Merit Cudkowicz, MD, MSc, director of the Sean M. Healey Center for ALS, has been named co-chair of the Optimizing Clinical Research Working Group for the 2022 National Institute of Neurological Disorders and Stroke (NINDS) ALS Strategic Planning Effort.
The Sean M. Healey International Prize for Innovation in ALS Research recognizes an individual or a team of investigators who catalyze exceptional discoveries leading to a transformative advance in therapy development in ALS.
The Gupta Family Endowed Prize for Innovation in ALS Care is an annual global prize to honor ground-breaking new approaches that lead to exceptional care for individuals living with amyotrophic lateral sclerosis (ALS).
HEALEY ALS Platform Trial Update: Zilucoplan arm stopped early for futility. HEALEY ALS Platform Trial Update: Zilucoplan arm stopped early for futility. We are extremely grateful to the many participants in the trial and the members of our patient
healey-platform-trial-hopes-to-bring-new-treatments-faster. healey-platform-trial-hopes-to-bring-new-treatments-faster. This study is really the first comprehensive platform for ALS drug development, where a central infrastructure is shared between a
The HEALEY ALS Platform Trial announces first participants enrolled for investigational product SLS-005 (Trehalose)
The HEALEY ALS Platform Trial announces first participants enrolled for investigational product SLS-005 (Trehalose). The HEALEY ALS Platform Trial announces first participants enrolled for investigational product SLS-005 (Trehalose). BOSTON – The
Mass General investigators receive the Cullen Education and Research Fund Medical Engineering Prize for ALS Research
The Cullen Education and Research Fund (CERF) announced the recipients of the first CERF Medical Engineering Prize for ALS Research: Leigh Hochberg, MD, PhD; Conor Walsh, PhD; and Sabrina Paganoni, MD, PhD.
The HEALEY ALS Platform Trial achieves enrollment goal for its fourth regimen (pridopidine). The HEALEY ALS Platform Trial achieves enrollment goal for its fourth regimen (pridopidine). Completing enrollment for the fourth regimen in the Platform
Transforming Medicine Through Innovation
Research at Massachusetts General Hospital integrates the full spectrum of "bench to bedside" discovery. Laboratory scientists work collaboratively with clinicians to make discoveries and turn them into treatments, diagnostics and devices that improve our quality of life.